Andrew DeCastro

Senior Director, Head of Scientific Communications & Multiple Myeloma Disease State Lead at Karyopharm Therapeutics Inc.


  • Post-doctoral Scholar, Tufts Medical Center, Molecular Oncology Research Institute
  • PhD, '14, Program in Experimental and Molecular Medicine, Dartmouth College
  • BS, '08, Pennsylvania State University

Selected Publications

  • DeCastro AJ, Dunphy KA, Hutchinson J, Balboni AL, Cherukuri P, Jerry DJ, DiRenzo J. MiR203 mediates subversion of stem cell properties during mammary epithelial differentiation via repression of ΔNP63α and promotes mesenchymal-to-epithelial transition. Cell Death Dis. 2013; 4:e514.

  • Balboni AL, Hutchinson JA, DeCastro AJ, Cherukuri P, Liby K, Sporn MB, Schwartz GN, Wells WA, Sempere LF, Yu PB, DiRenzo J. ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Res. 2013; 73(2):1020-30.

  • Cherukuri P, Decastro AJ, Balboni AL, Downey SL, Liu JY, Hutchinson JA, Direnzo J. Phosphorylation of ΔNp63α via a novel TGFβ/ALK5 signaling mechanism mediates the anti-clonogenic effects of TGFβ. PLoS One 2012; 7:e50066.

  • Kent S, Hutchinson J, Balboni A, Decastro A, Cherukuri P, Direnzo J. ΔNp63α promotes cellular quiescence via induction and activation of Notch3. Cell Cycle 2011; 10:3111-8.


Predoctoral Traineeship Award-Department of Defense (DOD) Breast Cancer Research Program (BCRP) of the Office of the Congressionally Directed Medical Research Programs (CDMRP), 2011-2014